Medscape review of new Gout research from EULAR 2024
- Phase 3 trial program for SEL-212
- Safety of SEL-212
- New Selective URAT1 Inhibitors - ruzinurad & AR882 https://t.co/szVRO2sqpu https://t.co/B9LcdpeCGd
Links:
New Options for Refractory Gout Are Showing Promise in Late-Phase Trials
https://buff.ly/4cGZ50H
Jul-17-2024
